ライフサイエンスコーパス: brain metastases

1 asia; NEL_INST: 11 patients, 33 lesions, all brain metastases).

2 in patients with HER2-positive breast cancer brain metastases.

3 (TLR) 9 agonist, CpG-C, is effective against brain metastases.

4 t to improve the treatment and prevention of brain metastases.

5 e to antiangiogenic treatment in gliomas and brain metastases.

6 here is a high risk of developing additional brain metastases.

7 ory accuracy in predicting the tumor type of brain metastases.

8 (62%) patients in the full analysis set had brain metastases.

9 velopment of gene and cell therapies against brain metastases.

10 ve longer and thus are at increased risk for brain metastases.

11 ted 20% of patients with cancer will develop brain metastases.

12 inib has not been studied in active melanoma brain metastases.

13 patients with EGFR-mutant NSCLC who develop brain metastases.

14 r improve outcomes in patients with melanoma brain metastases.

15 atus, extracranial metastases, and number of brain metastases.

16 months from the time of initial treatment of brain metastases.

17 with non-small-cell lung cancer (NSCLC) and brain metastases.

18 free survival were measured from the date of brain metastases.

19 alternative therapies for the management of brain metastases.

20 patients with newly diagnosed and untreated brain metastases.

21 in patients with BRAF(V600)-mutant melanoma brain metastases.

22 alteration data for patients with NSCLC and brain metastases.

23 brain radiotherapy (WBRT) each year to treat brain metastases.

24 with cancer hospitalized with a diagnosis of brain metastases.

25 2006 and 2014 with NSCLC and newly diagnosed brain metastases.

26 ls in the murine brain and in human melanoma brain metastases.

27 ry for a response to the antibodies in these brain metastases.

28 le which was CNS penetrant in order to treat brain metastases.

29 py in patients with untreated or progressive brain metastases.

30 -life endpoints into trials of patients with brain metastases.

31 or retrospective study focusing on melanoma brain metastases.

32 secondary ALK kinase domain mutations and/or brain metastases.

33 r cohort and refine it integrating number of brain metastases.

34 for use in clinical trials of treatment for brain metastases.

35 what metabolic changes benefit breast cancer brain metastases.

36 ligand (123)I-DPA-713 for early detection of brain metastases.

37 tral radiological review of individuals with brain metastases.

38 rst-line treatment for gliomas and recurrent brain metastases.

39 us toward new perspectives in understanding brain metastases.

40 acardially into female BALB/c mice to induce brain metastases.

41 tastatic breast cancer eventually developing brain metastases.

42 rt tumor and confirmed partial resolution of brain metastases.

43 s in a rodent model of breast adenocarcinoma brain metastases.

44 physiology, both for primary gliomas and for brain metastases.

45 ormance status of 2, and 18% of patients had brain metastases.

46 trategies for primary brain malignancies and brain metastases.

47 trast to (18)F-FDG PET, immuno-PET disclosed brain metastases.

48 ugs against primary brain tumours as well as brain metastases.

49 monotherapy for HER2-positive breast cancer brain metastases.

50 f pembrolizumab to treat small, asymptomatic brain metastases.

51 is safe in selected patients with untreated brain metastases.

52 tumor burden and reduced the average size of brain metastases.

53 mptoms and signs related to mass effect from brain metastases.

54 ry, ALK-positive NSCLC, including those with brain metastases.

55 ohort study of 293 patients with cancer with brain metastases (104 with therapeutic enoxaparin and 18

56 through 2014 with NSCLC and newly diagnosed brain metastases (1521 adenocarcinoma and 665 nonadenoca

57 ed 52 patients with untreated or progressive brain metastases (18 with melanoma, 34 with NSCLC), and

58 More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehyd

59 and HER2-negative primary breast cancers and brain metastases, (89)Zr-pertuzumab PET/CT suggested tha

60 n of elderly NSCLC patients with synchronous brain metastases (95% CI: 0.59-0.96, p: 0.020).

61 Lung cancer often has a poor prognosis, with brain metastases a major reason for mortality.

62 mainstay of treatment for many patients with brain metastases, a growing number of systemic options a

63 vailable treatment options for patients with brain metastases, a multidisciplinary approach is strong

64 However, number of brain metastases-a highly relevant clinical variable-is

65 inst refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the ef

66 tastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and ca

67 ter local treatment of one to three melanoma brain metastases, adjuvant WBRT does not provide clinica

68 aim to characterize patients with cancer and brain metastases admitted to hospitals nationwide and id

69 proximately 3% of patients hospitalized with brain metastases also had a diagnosis of ICH, which was

70 ndings suggest that for patients with 1 to 3 brain metastases amenable to radiosurgery, SRS alone may

71 f the brain because of the high incidence of brain metastases among patients with HER2-positive advan

72 Patients with stable brain metastases and an Eastern Cooperative Oncology Gro

73 f 94 patients with retrospectively confirmed brain metastases and at least one post-baseline MRI or C

74 ts in neurological outcome for patients with brain metastases and could potentially be tested in othe

75 patients with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI.

76 nstitutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the stud

77 portion and median survival of patients with brain metastases and newly diagnosed breast cancer.

78 nt of metastatic melanoma are active against brain metastases and offer new opportunities to improve

79 he treatment and management of patients with brain metastases and provide speculation on future resea

80 reclinical model of breast cancer-associated brain metastases and support continued investigation int

81 signaling in the promotion of breast cancer brain metastases and support the prognostic and therapeu

82 trate that somatic alterations contribute to brain metastases and that genomic sequencing of a suffic

83 models are critical to study the biology of brain metastases and to identify effective therapeutic a

84 wo patients who had 83 previously irradiated brain metastases and who underwent (18)F-FDOPA PET becau

85 ts who have received prior therapy for their brain metastases and whose CNS disease is radiographical

86 ample, 66% had primary brain tumors, 27% had brain metastases, and 8% underwent prophylactic cranial

87 comprised patients with previously untreated brain metastases, and cohort B comprised patients whose

88 arise evidence for the treatment of melanoma brain metastases, and discuss the rationale and evidence

89 yroid dysfunction or diabetes, had no active brain metastases, and had not received previous immune c

90 of 0 to 1, adequate organ function, treated brain metastases, and no recent vascular events or bleed

91 Performance Status (KPS), gender, status of brain metastases, and the status of primary lung cancer.

92 Brain metastases are a very common manifestation of canc

93 lications, future outcomes for patients with brain metastases are almost certain to improve.

94 Brain metastases are common and are usually detected by

95 Brain metastases are frequently treated with radiation.

96 as peripheral metastases, but patients with brain metastases are generally excluded because of the l

97 Glioblastomas and brain metastases are highly proliferative brain tumors w

98 ies for treating breast cancer patients with brain metastases are inefficient.

99 Background Brain metastases are manually identified during stereota

100 Brain metastases are more common than primary CNS tumors

101 as options for VTE treatment; patients with brain metastases are now addressed in the VTE treatment

102 Brain metastases are prevalent in various types of cance

103 Because brain metastases are responsible for life-threatening sy

104 Brain metastases are the most common intracranial tumors

105 Brain metastases are thought to occur via seeding of cir

106 (70% [53-83]) of 40 patients with measurable brain metastases as assessed by the independent review c

107 nt or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at scr

108 fied analyses based on prior cancer therapy, brain metastases at baseline, and sex showed similar tre

109 ted or locally treated neurologically stable brain metastases at baseline.

110 t of patients with follow-up had progressive brain metastases at death, and repeated interventions fo

111 ed to identify predictors of the presence of brain metastases at diagnosis and factors associated wit

112 estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacki

113 and 2013 for whom the presence or absence of brain metastases at diagnosis was known.

114 atients with ROS1 fusion-positive NSCLC have brain metastases at the diagnosis of advanced disease.

115 survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis.

116 We identified 968 patients with brain metastases at the time of diagnosis of breast canc

117 Patients with breast cancer and brain metastases at the time of diagnosis were identifie

118 the years 2010 through 2012 had synchronous brain metastases at the time of diagnosis, and Medicare

119 etastases, defined as new and/or progressive brain metastases at the time of study entry; and those w

120 he incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer.

121 Breast cancer brain metastases (BCBM) have a 5-20 year latency and acc

122 afts (PDXs) of HER2-expressing breast cancer brain metastases (BCBM), and their use for the identific

123 ed with increased incidence of breast cancer brain metastases (BCBM), but the mechanisms underlying t

124 0-16% of patients with breast cancer develop brain metastases (BCBM).

125 Breast cancer brain metastases (BM) affect younger women disproportion

126 Brain metastases (BM) are a devastating consequence of b

127 Brain metastases (BM) are the most common intracranial t

128 Brain metastases (BM) of colorectal cancer (CRC) are rar

129 lapsed (BCR) and their paired (n = 40 pairs) brain metastases (BM) using the NanoString(TM) nCounter(

130 Brain metastases (BMs) are the most common malignancy of

131 Brain metastases (BMs) occur in 10% to 20% of adult pati

132 eceptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant

133 Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options.

134 cluding low-grade and high-grade gliomas and brain metastases (BrMs) originating from diverse extracr

135 PDGFB protein expression was prognostic for brain metastases, but not metastases to other sites.

136 gnetic resonance imaging (MRI) to screen for brain metastases, but rather should have a low threshold

137 hage is frequently observed in patients with brain metastases, but that therapeutic anticoagulation d

138 ents with BRAF(V600)-mutant melanoma without brain metastases, but the median duration of response wa

139 frequently in patients with cancer who have brain metastases, but there is limited evidence supporti

140 Brain metastases can contribute to a decreased quality o

141 rogression-free survival among patients with brain metastases, confirmed objective response rate, and

142 st cancer, the incidence of life-threatening brain metastases continues to increase in some of these

143 in tumors, but its efficacy in patients with brain metastases could be better-studied.

144 lly stable at study entry; those with active brain metastases, defined as new and/or progressive brai

145 e key populations: those with treated/stable brain metastases, defined as patients who have received

146 actors found in 1833 patients with NSCLC and brain metastases diagnosed between 1985 and 2005: patien

147 We diagnosed the lesions as disseminated brain metastases due to lung cancer.

148 HER2-positive breast cancer with progressive brain metastases during or after treatment with trastuzu

149 In 39 of 45 brain metastases eligible for dynamic analysis, a wide r

150 Brain metastases encompass nearly 80% of all intracrania

151 r day) in four patient cohorts with melanoma brain metastases enrolled from 32 hospitals and institut

152 xpanding treatment options for patients with brain metastases, enrolment in clinical trials is essent

153 anticoagulation carefully for patients with brain metastases, especially those with melanoma and kid

154 A549 cells selected in vivo to give brain metastases exhibited cisplatin resistance and decr

155 Brain metastases expression changes in 127 genes within

156 stigated in patients with breast cancer with brain metastases for their ability to reduce CSFTC count

157 the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.

158 Patients with newly diagnosed brain metastases from 1996 to 2013 were identified.

159 Patients with brain metastases from ALK-rearranged NSCLC treated with

160 A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identifi

161 nti-miR10b into mice bearing lung, bone, and brain metastases from breast cancer resulted in selectiv

162 ntiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because the

163 tivity is limited in patients with untreated brain metastases from ccRCC.

164 FR and ALK inhibitors have shown activity on brain metastases from EGFR and ALK mutant non-small-cell

165 New inhibitors are being investigated in brain metastases from ER-positive or triple-negative bre

166 Clinically, we showed that brain metastases from human breast cancer patients expre

167 Brain metastases from lung adenocarcinoma (BM-LUAD) freq

168 The survival of patients with brain metastases from melanoma has substantially improve

169 tor pembrolizumab in patients with untreated brain metastases from melanoma or non-small-cell lung ca

170 ) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC)

171 rain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when hi

172 Pembrolizumab has activity in brain metastases from NSCLC with PD-L1 expression at lea

173 e analysis included radiomic features of 658 brain metastases from T1-weighted contrast material-enha

174 older with melanoma or NSCLC with untreated brain metastases from the Yale Cancer Center.

175 ecially feared complication in patients with brain metastases given the potential for significant mor

176 ble analysis of the breast-GPA and number of brain metastases (> three v </= three), both were indepe

177 gible patients were those with HER2-positive brain metastases (>/= 1 cm in longest dimension) who exp

178 l lesions in the liver and lungs whereas the brain metastases had nearly resolved.

179 Historically, the prognosis of patients with brain metastases has been poor; however, with new therap

180 f the biology and molecular underpinnings of brain metastases has greatly improved, resulting in more

181 s' ability to predict survival in NSCLC with brain metastases has improved significantly.

182 The incidence of brain metastases has increased as a result of improved s

183 The incidence of brain metastases has markedly increased in the past 20 y

184 Historically, patients with brain metastases have been excluded from most clinical t

185 Brain metastases have been shown to induce a robust glia

186 Historically, patients with brain metastases have been understudied, because of rest

187 In clinical specimens, brain metastases have elevated HIF1A protein expression,

188 n of extracranial disease control, number of brain metastases, histology, maximal resection cavity di

189 RAF(V600)-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib pl

190 primary breast tumors, and in patients with brain metastases, hypoxic signaling within CTCs predicts

191 Astrocyte reactivity associated with brain metastases impaired cerebrovascular responses to s

192 Forty-five brain metastases in 30 patients were included.

193 Results: Forty-five brain metastases in 30 patients were included.

194 in patients with HER2-positive breast cancer brain metastases in a multicenter, phase II open-label t

195 ith MRI radiomic image features of different brain metastases in a multiclass machine learning approa

196 F3 overexpression clinically correlates with brain metastases in breast cancer patients.

197 ith a lower survival and higher incidence of brain metastases in breast cancer patients.

198 ons regarding the inclusion of patients with brain metastases in clinical trials, as part of a broade

199 he inclusion of patients with treated/stable brain metastases in clinical trials.

200 d progression criteria for the assessment of brain metastases in clinical trials.

201 reader 4; P = .012) metastases and revealed brain metastases in five of 51 (10%) patients.

202 inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non-small-

203 The incidence of brain metastases in patients with lung cancer has increa

204 Pembrolizumab shows activity in brain metastases in patients with melanoma or NSCLC with

205 rradiation not only reduces the incidence of brain metastases in patients with SCLC and with non-meta

206 ll survival and increased risk of developing brain metastases in patients with TNBC.

207 ed against the potential benefit in terms of brain metastases incidence and survival.

208 s required to optimally manage patients with brain metastases, including consideration of radiation t

209 potential pathways to target ALK-rearranged brain metastases, including next generation ALK inhibito

210 val (OS) in patients with breast cancer with brain metastases, including the breast graded prognostic

211 Furthermore, overexpression of YTHDF3 in brain metastases is attributed to increased gene copy nu

212 We conclude that the T-cell response to brain metastases is not a surrogate of local tumor invas

213 eatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, i

214 egulation of SERPINB1, a protein elevated in brain metastases, led to a reduction in brain metastasis

215 that are focused on other tumors, including brain metastases, leptomeningeal metastases, spine tumor

216 racking; (3) outcome prediction in epilepsy, brain metastases, lumbar spinal stenosis, lumbar disc he

217 In this view, brain metastases may be conceptualized as progressive on

218 The treatment of multiple brain metastases (MBM) from melanoma is controversial an

219 ith mild vasogenic edema and four additional brain metastases measuring 4 to 9 mm in size.

220 examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ

221 may benefit NSCLC patients with synchronous brain metastases more than it does patients without intr

222 Therapeutic outcomes for patients with brain metastases need to improve.

223 organoids could be established directly from brain metastases not typically amenable to in vitro cult

224 ALK-positive non-small-cell lung cancer with brain metastases now have the potential to achieve a pro

225 velop brain metastases, with the majority of brain metastases occurring in those with lung, breast an

226 uzumab most likely fails in the treatment of brain metastases of breast cancer because of poor CNS pe

227 ormal breast tissues and stromal cultures of brain metastases of breast cancer had similar effects as

228 e against glioblastoma but generally fail in brain metastases of breast cancer.

229 in tumours, which face similar challenges to brain metastases of extracranial origin, and vice versa.

230 expression of PDGFRbeta(D849V) also promoted brain metastases of mammary tumor cells expressing high

231 REP1 accumulation in a large number of human brain metastases of various solid tumors, including NSCL

232 45,225 hospitalizations were associated with brain metastases, of which 4,145 (2.85%) had a concurren

233 Patients were excluded if they had active brain metastases or active autoimmune disease requiring

234 Among the patients with brain metastases, progression-free survival at 1 year wa

235 The Quality of Life after Treatment for Brain Metastases (QUARTZ) study is a non-inferiority, ph

236 s of search terms and synonyms for melanoma, brain metastases, radiation, chemotherapy, immunotherapy

237 The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an internati

238 he 6-month and 12-month freedom from distant brain metastases rates were 74.1% and 68.8%, respectivel

239 our newly improved models of patient-derived brain metastases recapitulate the histologic, molecular,

240 derstanding the molecular characteristics of brain metastases relative to the primary tumour so that

241 Development of brain metastases remains a substantial contributor to ov

242 , its role in the treatment of patients with brain metastases remains controversial.

243 Brain metastases represent the greatest clinical challen

244 und for 81 and 666 patients with and without brain metastases, respectively.

245 3-mediated astrocyte reactivity in rats with brain metastases restored cerebrovascular function, as s

246 radiation to the surgical cavity of resected brain metastases results in low rates of local failure.

247 , CSFTC) of nine breast cancer patients with brain metastases revealed dynamic changes in tumor cell

248 ical to distinguish recurrent or progressive brain metastases (RPBM) from late or delayed radiation i

249 s Patients with treated or clinically stable brain metastases should be routinely included in trials

250 Patients with brain metastases should receive appropriate local therap

251 had complete resection of one, two, or three brain metastases significantly lowers local recurrence c

252 s in understanding the mechanisms that drive brain metastases so that they can be targeted with preve

253 ld enable substantially earlier detection of brain metastases than the current clinical approach of g

254 gle-shot detector models detected nearly all brain metastases that were 6 mm or larger with limited f

255 s is the first description of a patient with brain metastases that were characterised by restricted d

256 Among patients with 1 to 3 brain metastases, the use of SRS alone, compared with SR

257 ger following the diagnosis and treatment of brain metastases, there has been rising concern about tr

258 of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plu

259 ailable specimens of matched fresh breast-to-brain metastases tissue and derived cells from patients

260 ng cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of PD-1 block

261 phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus

262 ung cancer (NSCLC) patients with synchronous brain metastases to identify predictors of the decision

263 ge was conferred by the ability of breast-to-brain metastases to take up and catabolize GABA into suc

264 However, the response of brain metastases to these drugs is poor, and it is hypot

265 status [0 vs 1-2] and presence or absence of brain metastases) to oral ceritinib 750 mg per day faste

266 astuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo

267 tases, and cohort B comprised patients whose brain metastases underwent prior therapy.

268 NSCLC patients with brain metastases unsuitable for surgical resection or st

269 Treatment of patients with multiple brain metastases using a single-isocenter volumetric mod

270 f orthotopic mouse models of patient-derived brain metastases via an improved intracarotid injection

271 Median survival among the entire cohort with brain metastases was 10.0 months.

272 Median OS after development of brain metastases was 49.5 months (95% CI, 29.0 months to

273 key considerations for patients with active brain metastases was developed.

274 ratified by EGFR mutation type and status of brain metastases, was done centrally using a validated n

275 To identify genomic alterations that promote brain metastases, we performed whole-exome sequencing of

276 Patients with brain metastases were allowed to enrol only if the lesio

277 and no history of TKIs before development of brain metastases were associated with improved survival

278 ses at death, and repeated interventions for brain metastases were common.

279 (89)Zr-pertuzumab PET/CT suggested that the brain metastases were HER2-positive.

280 Seventy-three patients with brain metastases were included: 39 in cohort A and 34 in

281 Brain metastases were manually identified and contoured

282 Patients with untreated brain metastases were not permitted to enrol in these tr

283 Patients with asymptomatic brain metastases were prospectively identified and under

284 tions in North America, patients with 1 to 3 brain metastases were randomized to receive SRS or SRS p

285 had local treatment of one to three melanoma brain metastases were randomly assigned to WBRT or obser

286 Historically, brain metastases were rarely investigated because patien

287 izumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated

288 specific role in spinal cord compression and brain metastases, where improved analgesia is a secondar

289 Patients with brain metastases who underwent radiation treatment 30-42

290 Pembrolizumab is active in melanoma brain metastases with acceptable toxicity and durable re

291 formance status who plan to receive WBRT for brain metastases with no metastases in the HA region.

292 s a single-arm phase II study of HA-WBRT for brain metastases with prespecified comparison with a his

293 and had a complete resection of one to three brain metastases (with a maximum diameter of the resecti

294 BRAF(V600E)-positive, asymptomatic melanoma brain metastases, with no previous local brain therapy,

295 F(V600D/K/R)-positive, asymptomatic melanoma brain metastases, with or without previous local brain t

296 (V600D/E/K/R)-positive, symptomatic melanoma brain metastases, with or without previous local brain t

297 BRAF(V600E)-positive, asymptomatic melanoma brain metastases, with previous local brain therapy, and

298 20% of all patients with cancer will develop brain metastases, with the majority of brain metastases

299 Patients with newly diagnosed brain metastases without prior local therapy and (18)F-F

300 Methods: Patients with newly diagnosed brain metastases without prior local therapy and (18)F-F